ANI Pharmaceuticals (ANIP) Competitors $64.96 -1.14 (-1.72%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$64.94 -0.02 (-0.04%) As of 07/11/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ANIP vs. ADMA, ANVS, LNTH, TLX, AXSM, AKRO, PCVX, KRYS, RYTM, and CYTKShould you be buying ANI Pharmaceuticals stock or one of its competitors? The main competitors of ANI Pharmaceuticals include ADMA Biologics (ADMA), Annovis Bio (ANVS), Lantheus (LNTH), Telix Pharmaceuticals (TLX), Axsome Therapeutics (AXSM), Akero Therapeutics (AKRO), Vaxcyte (PCVX), Krystal Biotech (KRYS), Rhythm Pharmaceuticals (RYTM), and Cytokinetics (CYTK). These companies are all part of the "pharmaceutical products" industry. ANI Pharmaceuticals vs. Its Competitors ADMA Biologics Annovis Bio Lantheus Telix Pharmaceuticals Axsome Therapeutics Akero Therapeutics Vaxcyte Krystal Biotech Rhythm Pharmaceuticals Cytokinetics ANI Pharmaceuticals (NASDAQ:ANIP) and ADMA Biologics (NASDAQ:ADMA) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation, analyst recommendations and media sentiment. Which has more volatility & risk, ANIP or ADMA? ANI Pharmaceuticals has a beta of 0.57, suggesting that its share price is 43% less volatile than the S&P 500. Comparatively, ADMA Biologics has a beta of 0.43, suggesting that its share price is 57% less volatile than the S&P 500. Does the media prefer ANIP or ADMA? In the previous week, ANI Pharmaceuticals had 2 more articles in the media than ADMA Biologics. MarketBeat recorded 6 mentions for ANI Pharmaceuticals and 4 mentions for ADMA Biologics. ADMA Biologics' average media sentiment score of 1.58 beat ANI Pharmaceuticals' score of 0.48 indicating that ADMA Biologics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ANI Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ADMA Biologics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Is ANIP or ADMA more profitable? ADMA Biologics has a net margin of 45.01% compared to ANI Pharmaceuticals' net margin of -3.12%. ADMA Biologics' return on equity of 47.16% beat ANI Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets ANI Pharmaceuticals-3.12% 21.35% 7.52% ADMA Biologics 45.01%47.16%30.51% Do institutionals and insiders hold more shares of ANIP or ADMA? 76.1% of ANI Pharmaceuticals shares are owned by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are owned by institutional investors. 11.1% of ANI Pharmaceuticals shares are owned by company insiders. Comparatively, 3.5% of ADMA Biologics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has higher valuation and earnings, ANIP or ADMA? ADMA Biologics has lower revenue, but higher earnings than ANI Pharmaceuticals. ANI Pharmaceuticals is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioANI Pharmaceuticals$614.38M2.29-$18.52M-$1.27-51.15ADMA Biologics$459.38M9.62$197.67M$0.8521.78 Do analysts prefer ANIP or ADMA? ANI Pharmaceuticals presently has a consensus target price of $78.88, suggesting a potential upside of 21.42%. ADMA Biologics has a consensus target price of $27.67, suggesting a potential upside of 49.47%. Given ADMA Biologics' stronger consensus rating and higher possible upside, analysts clearly believe ADMA Biologics is more favorable than ANI Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ANI Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00ADMA Biologics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 SummaryADMA Biologics beats ANI Pharmaceuticals on 10 of the 16 factors compared between the two stocks. Get ANI Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ANIP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ANIP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANIP vs. The Competition Export to ExcelMetricANI PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.43B$2.96B$5.62B$9.10BDividend YieldN/A2.39%5.24%4.00%P/E Ratio-51.1520.8528.1820.27Price / Sales2.29289.03428.7098.48Price / Cash8.7042.8637.4658.16Price / Book3.407.638.045.49Net Income-$18.52M-$55.05M$3.19B$250.45M7 Day Performance-0.51%8.43%3.62%4.79%1 Month Performance4.57%5.42%4.06%7.68%1 Year Performance2.30%2.03%30.00%16.43% ANI Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANIPANI Pharmaceuticals3.6644 of 5 stars$64.96-1.7%$78.88+21.4%+1.1%$1.43B$614.38M-51.15600News CoveragePositive NewsAnalyst ForecastAnalyst RevisionADMAADMA Biologics3.9596 of 5 stars$18.21+0.3%$27.67+51.9%+50.4%$4.34B$426.45M32.43530Positive NewsANVSAnnovis Bio1.565 of 5 stars$2.18+6.3%$30.25+1,287.6%-79.4%$39.95MN/A0.003LNTHLantheus4.5851 of 5 stars$81.86+0.5%$130.50+59.4%-34.2%$5.64B$1.53B14.22700News CoveragePositive NewsTLXTelix PharmaceuticalsN/A$16.07+0.4%$22.00+36.9%N/A$5.41B$516.72M0.00N/ANews CoverageAnalyst ForecastAXSMAxsome Therapeutics4.7407 of 5 stars$104.39+1.0%$172.33+65.1%+28.9%$5.09B$385.69M0.00380Analyst RevisionAKROAkero Therapeutics3.4071 of 5 stars$53.36-5.0%$82.50+54.6%+107.6%$4.48BN/A0.0030Insider TradePCVXVaxcyte1.8217 of 5 stars$32.51-0.2%$136.50+319.9%-56.2%$4.20BN/A0.00160News CoveragePositive NewsKRYSKrystal Biotech4.6823 of 5 stars$137.46-1.0%$211.13+53.6%-25.3%$4.01B$290.52M30.93210Trending NewsAnalyst ForecastInsider TradeAnalyst RevisionRYTMRhythm Pharmaceuticals3.1963 of 5 stars$63.19+0.7%$77.31+22.3%+86.1%$3.99B$130.13M0.00140Trending NewsAnalyst ForecastInsider TradeAnalyst RevisionCYTKCytokinetics4.0782 of 5 stars$33.04-0.4%$70.92+114.7%-34.3%$3.96B$18.47M-6.25250 Related Companies and Tools Related Companies ADMA Biologics Alternatives Annovis Bio Alternatives Lantheus Alternatives Telix Pharmaceuticals Alternatives Axsome Therapeutics Alternatives Akero Therapeutics Alternatives Vaxcyte Alternatives Krystal Biotech Alternatives Rhythm Pharmaceuticals Alternatives Cytokinetics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ANIP) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ANI Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ANI Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.